This core is designed to establish a facility and procedures for definitively testing whether an intervention treatment alters the rate of brain aging in rodent models. Although the NIA supports a Consortium that runs intervention clinical trials for select agents, there is growing recognition of a need for additional testing programs at the preclinical level. However, critical putative mechanisms and hypotheses of brain aging and AD are emerging from this PPG and elsewhere that warrant systematic testing. Long-term interventions are essentially the only way to test whether an experimental intervention alters the rate of gradual processes of aging and age-related pathology. Thus, there is a need for an intervention program that focuses on animal models of brain aging and AD. The program project has two parallel longitudinal components (at Universities of Kentucky and Alabama) and will assess the effectiveness of """"""""intervention treatments"""""""" in slowing the progression or alleviating aspects of brain aging and cognitive decline in a rat model of aging (F344 rats) and in a mouse model of AD (APP/PS1 mice). In F344 rats, the long-term interventions will be initiated at middle age, prior to the onset of cognitive decline. The same approach will be used in APP/PS1 mice. However, because of the accelerated pathology of this model, treatment will begin at 3 months, prior to cognitive decline and the appearance of pathological markers. The treatments chosen are compatible with long-term exposure and have few side effects. The four initial agents (minocycline, memantine, vitamin D, lipoic acid) test key hypotheses in various Projects of the PPG. All have compelling evidence for their potential efficacy against processes involved in aging and are currently approved for other indications in humans. A search of the clinical trials web site or the NIH CRISP database of sponsored grants reveals that none of these interventions are currently in clinicai/preciinical trial as aging interventions. Our use of these existing therapies as potential aging interventions, therefore, represents a novel use of these treatments. Thus, these candidate interventions appear to be highly feasible and there is substantial evidence indicating potentially favorable outcomes. Importantly, the selection of these agents for long-term tests is hypothesisdriven and will directly advance the aims of multiple Projects within the program project.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010836-13
Application #
7274274
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
13
Fiscal Year
2006
Total Cost
$375,868
Indirect Cost
Name
University of Kentucky
Department
Type
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Butterfield, D Allan; Palmieri, Erika M; Castegna, Alessandra (2016) Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Rev Proteomics 13:259-74
Chen, Chun-Hau; Li, Wenzong; Sultana, Rukhsana et al. (2015) Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiol Dis 76:13-23
Cenini, Giovanna; Fiorini, Ada; Sultana, Rukhsana et al. (2014) An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radic Biol Med 76:89-95
Barone, Eugenio; Di Domenico, Fabio; Mancuso, Cesare et al. (2014) The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol Dis 62:144-59
Förster, Sarah; Welleford, Andrew S; Triplett, Judy C et al. (2014) Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim Biophys Acta 1842:1333-9
Swomley, Aaron M; Förster, Sarah; Keeney, Jierel T et al. (2014) Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim Biophys Acta 1842:1248-57
Latimer, Caitlin S; Brewer, Lawrence D; Searcy, James L et al. (2014) Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc Natl Acad Sci U S A 111:E4359-66
Butterfield, D Allan; Di Domenico, Fabio; Barone, Eugenio (2014) Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta 1842:1693-706
Perluigi, Marzia; Di Domenico, Fabio; Buttterfield, D Allan (2014) Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. Proteomics Clin Appl 8:73-85
Farr, Susan A; Ripley, Jessica L; Sultana, Rukhsana et al. (2014) Antisense oligonucleotide against GSK-3? in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 67:387-95

Showing the most recent 10 out of 356 publications